Arbutus Biopharma Corporation Revenue 2011–2025
Arbutus Biopharma Corporation annual/quarterly revenue history and growth rate from 2011 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Arbutus Biopharma Corporation revenue for the quarter ending March 31, 2026 was 179.1 M, a 10054.54% increase year-over-year.
- Arbutus Biopharma Corporation revenue for the twelve months ending March 31, 2026 was 192.2 M, a 1976.26% increase year-over-year.
- Arbutus Biopharma Corporation annual revenue for 2025 was 14.1 M, a 128.21% increase from 2024.
- Arbutus Biopharma Corporation annual revenue for 2024 was 6.2 M, a 65.98% decrease from 2023.
- Arbutus Biopharma Corporation annual revenue for 2023 was 18.1 M, a 53.51% decrease from 2022.
- Arbutus Biopharma Corporation annual revenue for 2022 was 39.0 M.
Arbutus Biopharma Corporation (ABUS) — Frequently Asked Questions
Arbutus Biopharma Corporation (ABUS) is a publicly traded US company. It has a market capitalization of $789M. In fiscal 2025 it reported revenue of $14M and net income of -$34M. Explore ABUS's stock price, financial statements, earnings history, margins and key ratios below.
What is Arbutus Biopharma Corporation's market cap?
Arbutus Biopharma Corporation (ABUS) has a market capitalization of $789M.
What is the ABUS stock price?
ABUS trades at $4.12 (-3.06% on the day).
How much revenue does Arbutus Biopharma Corporation make?
Arbutus Biopharma Corporation reported revenue of $14M in fiscal 2025.
Is ABUS profitable?
In fiscal 2025, Arbutus Biopharma Corporation reported net income of -$34M.